MAB-anti-CD13

MAB-anti-CD13 is a monoclonal antibody currently in preclinical development by MAB DESIGNS. It is designed to target CD13, also known as Aminopeptidase N (APN), which is a zinc-dependent membrane-bound metalloprotease. CD13 is expressed on various cell types, including myeloid cells, pericytes, and endothelial cells, and is often overexpressed in various solid tumors and leukemias. It plays a critical role in cell migration, angiogenesis, and the degradation of extracellular matrix components. By binding to CD13, this antibody aims to inhibit its enzymatic activity or modulate its signaling functions, potentially serving as a therapeutic agent for oncology or inflammatory diseases.

Other names

anti-CD13 monoclonal antibodyanti-CD-13 monoclonal antibodyanti-CD 13 monoclonal antibodyCD13 monoclonal antibodyCD-13 monoclonal antibodyCD 13 monoclonal antibody